PMID- 11433610
OWN - NLM
STAT- MEDLINE
DCOM- 20010809
LR  - 20141120
IS  - 0031-2983 (Print)
IS  - 0031-2983 (Linking)
VI  - 93
IP  - 3
DP  - 2001 Jun
TI  - [Measurement of HER-2/neu in breast cancer: which methodologic approach?].
PG  - 183-8
AB  - HER-2/neu (c-erbB2) is overexpressed or amplified in 15%-35% of breast cancers. 
      HER-2 testing has become of paramount importance as it represents a key 
      therapeutic, prognostic and predictive parameter. HER-2 is associated with ER/PgR 
      negativity, high histologic grade, high proliferative index, and increased number 
      of metastatic lymph nodes. In N+ patients, HER-2 represents a negative prognostic 
      factor. HER-2 also represents a predictive factor. In fact, HER-2+ patients 
      appear to be resistant to the CMF regimen and comparatively more sensitive to 
      anthracyclins such as Herceptin. HER-2 testing is currently performed utilizing 
      two main methods: gene amplification is usually determined by fluorescence in 
      situ hybridization (FISH), whereas protein overexpression is determined by 
      immunohistochemistry (IHC). The comparison between FISH and IHC assays 
      demonstrates a considerably high degree of concordance (around 90%). When dealing 
      with cases scored as 3+ (according to the FDA licensed scoring method), such a 
      concordance approaches 100%. In consideration of greater technical simplicity as 
      well as of cost-effectiveness, IHC represents the ideal screening method for 
      HER-2 testing. FISH analysis remains valid for HER-2 evaluation in those cases in 
      which IHC fails to provide unequivocal data.
FAU - Orvieto, E
AU  - Orvieto E
AD  - Servizio di Anatomia Patologica e Citodiagnostica, Ospedale Civile di Treviso, 
      Piazza Ospedale 1, I-31100 Treviso.
FAU - Dei Tos, A P
AU  - Dei Tos AP
LA  - ita
PT  - Comparative Study
PT  - Editorial
PT  - English Abstract
TT  - Determinazione di HER-2/neu nel carcinoma mammario: quale approccio metodologico?
PL  - Italy
TA  - Pathologica
JT  - Pathologica
JID - 0401123
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/drug therapy/*genetics/mortality
MH  - Carcinoma/drug therapy/*genetics/mortality
MH  - Chemotherapy, Adjuvant
MH  - Cost-Benefit Analysis
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-1
MH  - Humans
MH  - *Immunohistochemistry/economics
MH  - *In Situ Hybridization, Fluorescence/economics
MH  - Mass Screening/economics
MH  - Neoplasm Proteins/*analysis/biosynthesis
MH  - Prognosis
MH  - Receptor, ErbB-2/*analysis/biosynthesis
MH  - Reproducibility of Results
EDAT- 2001/07/04 10:00
MHDA- 2001/08/10 10:01
CRDT- 2001/07/04 10:00
PHST- 2001/07/04 10:00 [pubmed]
PHST- 2001/08/10 10:01 [medline]
PHST- 2001/07/04 10:00 [entrez]
PST - ppublish
SO  - Pathologica. 2001 Jun;93(3):183-8.